Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-case post-marketing survey of Opdivo in recurrent or distant metastatic head and neck cancer
jRCT1080224012Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in head and neck cancer (HNC), sponsored by Ono Pharmaceutical. Started Jul 2018; status: completed.
02
Drugs
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on jRCT1080224012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224012.